Christiane Gradl
Sankt Poelten, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Disease Course After Anti-CD20 Discontinuation in Secondary Progressive Multiple Sclerosis-A Multicenter Long-Term Longitudinal Study.
Journal: Annals of clinical and translational neurology
Published: May 07, 2026
The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.
Journal: Journal of neurology
Published: March 14, 2026
Risk stratification for disease reactivation after therapy de-escalation/discontinuation in relapsing multiple sclerosis by the VIAADISC score.
Journal: Multiple sclerosis and related disorders
Published: November 29, 2024
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome.
Journal: European journal of neurology
Published: October 14, 2024
Association of Disease-Modifying Treatment With Outcome in Patients With Relapsing Multiple Sclerosis and Isolated MRI Activity.
Journal: Neurology
Published: August 28, 2024
Impact of vaccination on COVID-19 outcome in multiple sclerosis.
Journal: European journal of neurology
Published: July 06, 2022
Long-term outcome after COVID-19 infection in multiple sclerosis: a nation-wide multicenter matched-control study.
Journal: European journal of neurology
Published: May 03, 2022
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: October 01, 2021
COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: Insights from a nation-wide Austrian registry.
Journal: PloS one
Published: April 14, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026